Two case reports of vinorelbine extravasation: management and review of the literature.
Vinorelbine tartrate (Navelbine, Burroughs Wellcome Company, Research Triangle Park, NC, USA) is a semisynthetic vinca alkaloid approved in many countries for the first-line treatment of patients with advanced non-small-cell lung cancer. It is also used in the treatment of advanced breast and ovarian cancers and lymphoma. Like other vinca alkaloids, Navelbine can cause skin necrosis as a consequence of inadvertent extravasation in surrounding tissues during intravenous administration. In such cases, early treatment is strongly advocated. There is no documented case of vinorelbine extravasation in the literature. The authors herein report two cases successfully treated with hyaluronidase injections plus saline flushout under local anesthesia.
Cicchetti
S
S
Department of Plastic and Reconstructive Surgery, Mount Vernon Hospital, Northwood, Great Britain. silviacic@yahoo.it
Jemec
B
B
Gault
D T
DT
D000772:Anesthesia, Local; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005260:Female; D006230:Hand Injuries / Q000188:drug therapy*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012965:Sodium Chloride / Q000627:therapeutic use; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D012965:Sodium Chloride; D014747:Vinblastine; D006821:Hyaluronoglucosaminidase; D000077235:Vinorelbine